These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

179 related items for PubMed ID: 18778854

  • 21.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 22. Inhibition of RANKL-mediated osteoclast differentiation by selective TRAF6 decoy peptides.
    Poblenz AT, Jacoby JJ, Singh S, Darnay BG.
    Biochem Biophys Res Commun; 2007 Aug 03; 359(3):510-5. PubMed ID: 17544369
    [Abstract] [Full Text] [Related]

  • 23.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 24. Inhibitory effect of (-)-saucerneol on osteoclast differentiation and bone pit formation.
    Kim SN, Kim MH, Kim YS, Ryu SY, Min YK, Kim SH.
    Phytother Res; 2009 Feb 03; 23(2):185-91. PubMed ID: 18690659
    [Abstract] [Full Text] [Related]

  • 25. Receptor activator of nuclear factor-kappa B ligand induces osteoclast formation in RAW 264.7 macrophage cells via augmented production of macrophage-colony-stimulating factor.
    Islam S, Hassan F, Tumurkhuu G, Dagvadorj J, Koide N, Naiki Y, Yoshida T, Yokochi T.
    Microbiol Immunol; 2008 Dec 03; 52(12):585-90. PubMed ID: 19120972
    [Abstract] [Full Text] [Related]

  • 26.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 27.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 28. Amelogenin is a negative regulator of osteoclastogenesis via downregulation of RANKL, M-CSF and fibronectin expression in osteoblasts.
    Nishiguchi M, Yuasa K, Saito K, Fukumoto E, Yamada A, Hasegawa T, Yoshizaki K, Kamasaki Y, Nonaka K, Fujiwara T, Fukumoto S.
    Arch Oral Biol; 2007 Mar 03; 52(3):237-43. PubMed ID: 17101114
    [Abstract] [Full Text] [Related]

  • 29. Aldehydic components of cinnamon bark extract suppresses RANKL-induced osteoclastogenesis through NFATc1 downregulation.
    Tsuji-Naito K.
    Bioorg Med Chem; 2008 Oct 15; 16(20):9176-83. PubMed ID: 18823786
    [Abstract] [Full Text] [Related]

  • 30. The role of OPG/TRAIL complex in multiple myeloma: the OPG/TRAIL complex in an in vitro osteoclastogenesis model derived from human multiple myeloma-bone disease.
    Brunetti G, Colucci S, Rizzi R, Mori G, Colaianni G, Oranger A, Zallone A, Liso V, Grano M.
    Ann N Y Acad Sci; 2006 Apr 15; 1068():334-40. PubMed ID: 16831934
    [Abstract] [Full Text] [Related]

  • 31. Bortezomib Inhibits Osteoclastogenesis and Porphyromonas gingivalis Lipopolysaccharide-induced Alveolar Bone Resorption.
    Kim YG, Kang JH, Kim HJ, Kim HJ, Kim HH, Kim JY, Lee Y.
    J Dent Res; 2015 Sep 15; 94(9):1243-50. PubMed ID: 26130255
    [Abstract] [Full Text] [Related]

  • 32. The proteasome inhibitor bortezomib stimulates osteoblastic differentiation of human osteoblast precursors via upregulation of vitamin D receptor signalling.
    Kaiser MF, Heider U, Mieth M, Zang C, von Metzler I, Sezer O.
    Eur J Haematol; 2013 Apr 15; 90(4):263-72. PubMed ID: 23311753
    [Abstract] [Full Text] [Related]

  • 33. Bone scan images reveal increased osteoblastic function after bortezomib treatment in patients with multiple myeloma.
    Lee SE, Min CK, Yahng SA, Cho BS, Eom KS, Kim YJ, Kim HJ, Lee S, Cho SG, Kim DW, Lee JW, Min WS, Park CW.
    Eur J Haematol; 2011 Jan 15; 86(1):83-6. PubMed ID: 20946110
    [Abstract] [Full Text] [Related]

  • 34. Targeting MEK induces myeloma-cell cytotoxicity and inhibits osteoclastogenesis.
    Tai YT, Fulciniti M, Hideshima T, Song W, Leiba M, Li XF, Rumizen M, Burger P, Morrison A, Podar K, Chauhan D, Tassone P, Richardson P, Munshi NC, Ghobrial IM, Anderson KC.
    Blood; 2007 Sep 01; 110(5):1656-63. PubMed ID: 17510321
    [Abstract] [Full Text] [Related]

  • 35.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 36. Multiple roles of M-CSF in human osteoclastogenesis.
    Hodge JM, Kirkland MA, Nicholson GC.
    J Cell Biochem; 2007 Oct 15; 102(3):759-68. PubMed ID: 17516513
    [Abstract] [Full Text] [Related]

  • 37. Cooperation between Apo2L/TRAIL and bortezomib in multiple myeloma apoptosis.
    Balsas P, López-Royuela N, Galán-Malo P, Anel A, Marzo I, Naval J.
    Biochem Pharmacol; 2009 Mar 01; 77(5):804-12. PubMed ID: 19100720
    [Abstract] [Full Text] [Related]

  • 38. Bavachalcone inhibits osteoclast differentiation through suppression of NFATc1 induction by RANKL.
    Park CK, Lee Y, Chang EJ, Lee MH, Yoon JH, Ryu JH, Kim HH.
    Biochem Pharmacol; 2008 Jun 01; 75(11):2175-82. PubMed ID: 18433733
    [Abstract] [Full Text] [Related]

  • 39. [Technetium 99Tc methylenediphosphonate inhibits osteoclast formation from PBMCs in patients with rheumatoid arthritis].
    Ji Y, Huo X, Zhang H.
    Zhong Nan Da Xue Xue Bao Yi Xue Ban; 2009 Jul 01; 34(7):684-8. PubMed ID: 19648688
    [Abstract] [Full Text] [Related]

  • 40.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 9.